Advertisement
Table 4 Switching between TNF and non-TNF biologic DMARDs
| Prior biologic | Number (% of all prior biologic DMARDs) | Number of switches (% of each prior biologic DMARD) | Adjusteda OR of any switch (95% CI) | Switch to TNF or to non-TNF inhibitorsb | |
|---|---|---|---|---|---|
| Number of switches to TNF inhibitors (%) | Number of switches to non-TNF inhibitors (%) | ||||
| TNF inhibitors | |||||
| Etanercept | 11,753 (50.6) | 1223 (10.4) | Reference | 989 (80.9) | 234 (19.1) |
| Adalimumab | 5119 (22.0) | 732 (14.3) | 1.22 (1.10, 1.35) | 573 (78.3) | 159 (21.7) |
| Certolizumab | 104 (0.4) | 20 (19.2) | 1.44 (0.86, 2.39) | 8 (40.0) | 12 (60.0) |
| Golimumab | 130 (0.6) | 35 (26.9) | 2.24 (1.48, 3.37) | 22 (62.9) | 13 (37.1) |
| Infliximab | 5102 (22.0) | 567 (11.1) | 1.06 (0.95, 1.19) | 377 (66.5) | 190 (33.5) |
| Non-TNF inhibitor biologic agents | |||||
| Abatacept | 407 (1.8) | 70 (17.2) | 1.31 (0.99, 1.72) | 40 (57.1) | 30 (42.9) |
| Anakinra | 260 (1.1) | 85 (32.7) | 3.20 (2.41, 4.25) | 79 (92.9) | 6 (7.1) |
| Rituximab | 334 (1.4) | 27 (8.1) | 0.57 (0.38, 0.85) | 16 (59.3) | 11 (40.7) |
| Tocilizumab | 22 (0.1) | 2 (9.1) | 0.59 (0.14, 2.60) | 0 (0.0) | 2 (100) |
| Total | 23231 (100) | 2761 (11.9) | — | 743 (76.2) | 657 (23.8) |
